Michael J. Xiao

Michael J. Xiao

Auto-generated profile, based on publicly available information

Michael J. Xiao

Laboratory of Metabolic Regulation and Genetics, The Rockefeller University, New York, New York

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2019 in Blood
Verified
Journal Article
Open access
PDF file
APAmi B. Patel
Ami B. Patel
AFAnca Franzini
Anca Franzini
ELEmilie Leroy
Emilie Leroy
SKSoo Jin Kim
Soo Jin Kim
APAnthony D. Pomicter
Anthony D. Pomicter
MDMichael Deininger
Michael Deininger
The authors describe recurrent novel insertion/deletion mutations in the JH2 domain of JAK2 occurring in patients with eosinophilia as a prominent feature of their myeloproliferative neoplasms. Remarkably, 2 of the patients with a specific mutation (Leu583-Ala586DelInsSer) meet the criteria for both chronic eosinophilic leukemia and polycythemia vera, suggesting that this may be a distinct overlap syndrome.

31 July 2025 in Cancer Discovery
Verified
Journal Article
Closed access
HYHsi-Wen Yeh
Hsi-Wen Yeh
NDNicole Lauren DelGaudio
Nicole Lauren DelGaudio
BUBeste Uygur
Beste Uygur
AMAlon Millet
Alon Millet
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy
Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression. Significance: Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.

1 September 2014 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
MXMichael Xiao
Michael Xiao
AHAlbert V. Helsing
Albert V. Helsing
PLPhilip M. Lynch
Philip M. Lynch
AEAtif El-Naggar
Atif El-Naggar
MAMelissa M. Alegre
Melissa M. Alegre
KOKim L. ONeill
Kim L. ONeill

2 December 2025
Verified
Other
Open access
HYHsi-Wen Yeh
Hsi-Wen Yeh
NDNicole Lauren DelGaudio
Nicole Lauren DelGaudio
BUBeste Uygur
Beste Uygur
AMAlon Millet
Alon Millet
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy
Cancer cells require substantial metabolic adaptations to metastasize to distant organs, but the metabolites essential for successful colonization remain poorly defined. In this study, we used a mitochondrial metabolomics approach to compare primary and metastatic breast cancer cells. This analysis revealed accumulation of mitochondrial glutathione (GSH) during lung metastasis, driven by elevated expression of SLC25A39, a mitochondrial GSH transporter. Loss of SLC25A39 impairs metastatic colonization in genetic screens, cell line models, and patient-derived xenografts, without affecting primary tumor growth. Mitochondrial GSH import is specifically required during early colonization and functions independently of its canonical antioxidant role. CRISPR activation screens identified ATF4, a stress-induced transcription factor, as a bypass mechanism that restores metastatic potential in SLC25A39-deficient cells. Mechanistically, SLC25A39 is required for optimal ATF4 activation during metastasis and under hypoxia, linking mitochondrial GSH availability to integrated stress response signaling. These findings identify mitochondrial GSH as a necessary and limiting metabolite for metastatic progression.Significance:Mitochondrial GSH import via SLC25A39 is essential for early metastatic colonization in breast cancer, linking metabolic adaptation to stress response signaling. Targeting this pathway may uncover a therapeutic vulnerability specific to metastasis without affecting primary tumor growth.

2 December 2025
Verified
Other
Open access
HYHsi-Wen Yeh
Hsi-Wen Yeh
NDNicole Lauren DelGaudio
Nicole Lauren DelGaudio
BUBeste Uygur
Beste Uygur
AMAlon Millet
Alon Millet
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy
In vivo CRISPR screening of breast cancer cell lines during metastasis

2 December 2025
Verified
Other
Open access
HYHsi-Wen Yeh
Hsi-Wen Yeh
NDNicole Lauren DelGaudio
Nicole Lauren DelGaudio
BUBeste Uygur
Beste Uygur
AMAlon Millet
Alon Millet
AKArtem Khan
Artem Khan
KBKıvanç Birsoy
Kıvanç Birsoy
Spatial metabolomics of metastatic breast cancers